News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Endo Pharmaceuticals (ENDP) Lobbies to Protect Its Big Seller


5/30/2012 7:55:55 AM

One of the few bills moving through Congress with bipartisan support this spring would speed government approval of lower-cost generic copies of brand-name drugs. But one company, with help from an influential former congressman, is lobbying to protect its most lucrative brand-name product against generic competition and appears to have had some success in the House, potentially altering the bill to make it more favorable for the company.

Read at New York Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES